Melanoma and other skin tumours
Invited discussant abstracts 1106O and 1107O
Date
08 Oct 2016Session
Melanoma and other skin tumoursPresenters
Olivier MichielinAuthors
O.A. MichielinAuthor affiliations
- Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3696 - Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
Presenter: Caroline Robert
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
2724 - Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Presenter: Rajat Rai
Session: Melanoma and other skin tumours
Resources:
Abstract
3426 - Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
Presenter: Patrick Hwu
Session: Melanoma and other skin tumours
Resources:
Abstract
3381 - PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
Presenter: Georgina Long
Session: Melanoma and other skin tumours
Resources:
Abstract
3926 - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
Presenter: Paolo Ascierto
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Invited discussant LBA39, LBA40 and abstract 1111O
Presenter: Céleste Lebbé
Session: Melanoma and other skin tumours
Resources:
Slides
Invited discussant abstracts 1112PD, 1113PD and 1114PD
Presenter: Christian Blank
Session: Melanoma and other skin tumours
Resources:
Slides
Webcast
Invited discussant abstracts 1108PD, 1109PD and 1110PD
Presenter: Axel Hauschild
Session: Melanoma and other skin tumours
Resources:
Slides
Webcast
1679 - Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
Presenter: Jason Chesney
Session: Melanoma and other skin tumours
Resources:
Abstract
2037 - Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
Presenter: Antoni Ribas
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.